JAK2 and myeloproliferative neoplasm: Ruxolitinib, a potent and selective JAK1/JAK2 inhibitor significantly inhibited interleukin-6 signaling and proliferation of cells that harbor JAK2-V617F mutation [28], and presently, is being investigated in clinic in patients with myeloproliferative neoplasms (MPNs) [29].